Caplin Point Labs acquires 10 ANDAs, targets $473M US market

The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025

Establishment Labs seeks FDA nod for Motiva breast reconstruction implants

Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation

Wockhardt’s WCK 5222 earns accelerated review from European Medicines Agency

The accelerated review covers WCK 5222 for multiple critical infections

Diamyd Medical accelerates Phase 3 Type 1 diabetes trial following FDA guidance

The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026

Sinopia Biosciences scores NIH grant to supercharge AI-driven drug discovery

The funding will accelerate Sinopia’s data-driven drug discovery efforts

Edgewise Therapeutics reports positive updates from HCM drug EDG-7500

CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM

CPHI & PMEC India 2025 ignites pharma innovation and partnerships

For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows

Govt cancels registration of popular cosmetic product over misleading claims

The cancellation underscores the regulator’s strict stance against misleading cosmetic claims

US House passes Bill reauthorizing FDA rare disease incentive program

Briefs: CuraTeQ Biologics, Sigachi Industries and Natural Capsules

CuraTeQ Biologics and BioFactura USA to terminate agreement mutually